Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Nuvation Bio (NYSE:NUVB) Falls as Biotech Buyers Step Back

● No clinical-trial readout, regulatory decision, financing orPartnershipannouncement, management change or analyst action could be dated to the session.

Nitish Kishor | 05 October 2026

OKYO Pharma (NASDAQ:OKYO) Advances as Penny Biotech Draws Fresh Interest

● No company-specific announcement was found for OKYO Pharma, and the advance reflects speculative biotech and low-float momentum.

Nitish Kishor | 05 October 2026

Prenetics Global (NASDAQ:PRE) Dips as Health Technology Name Lags the Advance

● NoEarningsrelease, operational update, financing event or regulatory development tied to the session could be confirmed.

Nitish Kishor | 05 October 2026

Quantum-Si Incorporated (NASDAQ:QSI) Jumps as Life Science Tools Stock Takes Off

● NoEarningsrelease, data readout, partnership, product announcement or analyst action could be tied to the session.

Nitish Kishor | 05 October 2026

Integra LifeSciences (NASDAQ:IART) Sinks on Lowered 2026 Guidance After a Flooding Disruption

● Integra LifeSciences closed at $12.68 on Friday, October 2, 2026, a decline of 21.19% on the session.

Nitish Kishor | 05 October 2026

ImmunityBio (NASDAQ:IBRX) Rises as Biotech Speculation Picks Up

● No company-specific announcement was found for ImmunityBio, and the advance reflects speculative biotech and momentum trading.

Nitish Kishor | 05 October 2026

Immatics (NASDAQ:IMTX) Slips as Clinical-Stage Biotech Shares Retreat

● A review of reporting surfaced no clinical update,Earningsrelease, regulatory development, financing,Partnershipor analyst action behind the decline.

Nitish Kishor | 05 October 2026

Immunic (NASDAQ:IMUX) Declines as Investors Pass Over Clinical-Stage Biotech

● No clinical readout, regulatory update, financing disclosure or corporate announcement tied to the session could be confirmed.

Nitish Kishor | 05 October 2026

Indaptus Therapeutics (NASDAQ:INDP) Pops as Biotech Speculators Return

● No clinical-trial result, regulatory decision, financing,Partnershipor analyst action could be tied to the session.

Nitish Kishor | 05 October 2026

Cardiol Therapeutics (NASDAQ:CRDL) Falls as Low-Priced Biotech Pulls Back

● Cardiol Therapeutics closed at $1.41 on Friday, October 2, 2026, a decline of 9.62% on the session.

Nitish Kishor | 05 October 2026
Support

Hi! How can we help you today?

Loading…